TFF Pharmaceuticals Q3 EPS $(0.09) Beats $(0.11) Estimate, Sales $234.76K Beat $50.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
TFF Pharmaceuticals (NASDAQ:TFFP) reported Q3 earnings with an EPS of $(0.09), surpassing the $(0.11) estimate, marking an 18.18% beat and a 68.97% improvement from last year's $(0.29) per share. Sales reached $234.76K, exceeding the $50K estimate by 369.53% and showing a 168.04% increase from the previous year's $87.59K.
November 14, 2023 | 9:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TFF Pharmaceuticals reported a strong Q3 with EPS and sales beating estimates, indicating a positive trend in financial performance compared to the previous year.
TFF Pharmaceuticals' better-than-expected earnings and sales figures are likely to instill investor confidence and could lead to a short-term increase in stock price. The significant beat on both EPS and sales estimates, along with the substantial year-over-year growth, are positive indicators that may attract investor interest and drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100